Verdiva Bio secures £333.5m Series A led by Forbion and General Atlantic to develop next-gen weight loss therapies

Verdiva Bio develops next-generation obesity and metabolic disease therapies, advancing oral and injectable treatment candidates to improve access, adherence and long-term outcomes.